Legend Biotech Corporation LEGN
21.48 USD +0.38 (+1.80%)
At closeNov 3, 2026, 4:22 PM EST
21.49 +0.01 +0.05%
After hours · Nov 3, 4:22 PM ET
21.12 Day range 21.67
16.65 52-week range 36.28
- YTD
- -1.20%
- 1 year
- -33.15%
Analyst view
Consensus: buy
Buy
Price target (mean) 45.62 +112.4% upside
Now 21.48
- Target (low)
- 24.00
- Target (mean)
- 45.62
- Target (high)
- 68.00
Ratings (0m) 13 8 buy · 5 hold · 0 sell
- Strong buy5
- Buy3
- Hold5
- Sell0
- Strong sell0
Recommendation trend
- This month 13
- 1 month ago 13
- 2 months ago 15
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.01 | 0.01 – 0.01 | -0.22 | +104.6% | 359.91M | +32.2% | 1 |
| Next quarter | 0.09 | 0.09 – 0.09 | -0.16 | +156.3% | 382.01M | +24.7% | 1 |
| Current year | -0.01 | -0.01 – -0.01 | -1.60 | +99.4% | 1.44B | +39.7% | 1 |
| Next year | 0.6831 | 0.3162 – 1.05 | -0.01066 | +6508.1% | 1.77B | +23.4% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | Barclays | Maintained | Overweight | Overweight |
| Oct 9, 2026 | JP Morgan | Maintained | Neutral | Neutral |
| Oct 8, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Sep 30, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 11, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 4, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 12, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 12, 2026 | TD Cowen | Maintained | Hold | Hold |
| Aug 12, 2026 | Oppenheimer | Downgrade | Outperform | Perform |
| Aug 12, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 12, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jul 28, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 27, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jul 24, 2026 | UBS | Downgrade | Buy | Neutral |
| Jul 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jun 3, 2026 | UBS | Maintained | Buy | Buy |
| Jun 3, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 18, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 13, 2026 | TD Cowen | Maintained | Hold | Hold |
| May 13, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| May 13, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Apr 21, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 15, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 11, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Mar 11, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Feb 4, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jan 22, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jan 22, 2026 | TD Cowen | Downgrade | Buy | Hold |
| Jan 20, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jan 7, 2026 | Oppenheimer | Initiated | — | Outperform |